Why don't your senior colleagues echo your optimism about timescales?
I sometimes call this one "The curious case of the catatonic biogerontologists"...
The SENS strategy as described here purports to have all the characteristics
that should make it persuasive: it's detailed, it's thorough and it's all
firmly based on established experimental work in the various relevant areas
of biology. So, you may well ask, where's the catch? Why, on all the many
documentaries on aging that remain so popular, don't my colleagues come out
and advocate the work that I advocate?
There are three main reasons why most mainstream gerontologists remain
so conspicuously absent from the growing band of vocal advocates of the
SENS approach to curing aging. They are all understandable, but given
the importance of the problem and the key role that senior specialists
play in determining public opinion and hence public policy, I feel that
none of them is a legitimate excuse.
The central reason is simple ignorance of the relevant science. Biology
-- even human biology -- is a very big subject, so nobody can hope to
understand it all in depth. Thus, biologists restrict themselves to
understanding in depth a rather narrow subset of biology and they trust
each other to focus on the other areas. Unfortunately, this strategy
relies utterly on having a good instinct for when an area not hitherto
perceived as relevant to one's own area has become so as a result of a
new piece of work. Most of the areas that I have introduced into the
biology of aging have so far received only limited attention because
most biogerontologists don't instinctively see how they could be useful.
The second reason is really subsidiary to the first, in that its
importance is in sustaining the ignorance I just referred to. The
progress of ideas always has enormous inertia, on account of the
emotional, intellectual and financial investment that those who hold
conventional views have made in those views. Scientists, like others,
find it difficult to write off that investment and embrace a new
paradigm even when the argument for that new paradigm is very
comprehensive. This manifests as a reluctance to consult relevant
scientific literature, for example, or even to entertain the idea that
such literature is relevant in the first place. It also manifests as a
preference for avoiding overt debate on such matters, since any such
debate opens up the risk of being forced to acknowledge the superiority
of the new paradigm. None of this is conscious, but it is an
indescribably powerful force against progress. In this case, the
idea that reversing aging might be easier than slowing it down a bit
is so counter-intuitive that many of my colleagues are inclined to
dismiss it out of hand before taking the time to look at my argument
in detail.
The third reason my colleagues mostly don't say what I say is political.
Scientists prefer to promote and discuss what they're working on. They
aren't so keen to tell people that they would be working on something
altogether more interesting or ambitious if only their funders had the
imagination and courage to fund it, because that's a quick way to lose
funding even for unambitious work. Now, you might ask, why are funders
so unambitious? In industry it's because of short-termism, of course:
firms that can make money quickly and certainly with boring products
will do so in preference to making money far in the future and with
much less certainty with ambitious products, even if the amount of
money on offer in the latter case is far bigger. In the public sector,
the main reason is that funders don't want to be thought to be wasting
tax-payers' money on blue-sky work with no chance of success. So, the
ultimate problem is the pessimism of voters. But, of course, that
pessimism is due precisely to what senior biogerontologists say and
don't say on the television... This "triangular log-jam" (see below)
is the fundamental problem with getting more money into life extension
research. The strange arrows with flat heads are a notation used in
genetics; they mean "inhibits".

It can be unblocked at any corner, of course. My work is focused on
the "biogerontologists" corner because I know them all personally and
because they are few in number. The quickest way to change the minds of
scientists regarding research priorities, however, is to remember that
scientists will do anything interesting for food. Hence, an alternative
supply of funds is a solution:

Finally, both the scientists and the prospective philanthropists may
be encouraged to take the plunge if a bit of publicity comes their
way:

and this is one motivation for the Methuselah Mouse Prize.
In conclusion I should stress that many of my colleagues, on reading or
hearing the castigation of them that I have rehearsed above, would say
that in fact there is a wholly responsible reason why they are cautious
in their public predictions of the rate of progress: namely, they think
it would be irresponsible to engender unwarranted optimism. My answer
is that experts can mislead the public just as powerfully by silence as
by speaking out, if the public are predisposed to be pessimistic on the
scientific issue in question, as they certainly are in this case. I
therefore claim that biogerontology is a case where the general rule of
not getting people's hopes up unduly is being taken too far. I have
said so in print here.